Ironwood Pharmaceuticals
IRWD
149 hedge funds and large institutions have $2.48B invested in Ironwood Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 63 increasing their positions, 39 reducing their positions, and 28 closing their positions.
62% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 39
23% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $10.4M
7.5% more ownership
Funds ownership: 131.45% → 138.95% (+7.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
11% less funds holding
Funds holding: 167 → 149 (-18)
11% less capital invested
Capital invested by funds: $2.78B → $2.48B (-$305M)
54% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$46.3M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$46.1M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$28M |
| 4 |
BM
Bridger Management
New York
|
+$23.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.9M |
| 2 |
Renaissance Technologies
New York
|
-$11.9M |
| 3 |
Goldman Sachs
New York
|
-$10.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.63M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.01M |
IRWD Hedge Fund Activity: Q3 2017 in Review
149 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2017, worth a combined $2.48B — down 11% from $2.78B a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of IRWD and 13 opened new positions — a net loss of 15 holders — while 39 trimmed existing stakes and 63 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $46.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $15.9M sold.
- 149 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2017, down from 167 in Q2 2017.
- Funds reported $2.48B of Ironwood Pharmaceuticals stock for Q3 2017, down 11% quarter-over-quarter.
- 13 funds opened new Ironwood Pharmaceuticals positions in Q3 2017 and 28 closed out, a net change of -15 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2017 was BVF Inc, an estimated $46.3M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2017 was Point72 Asset Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2017.